Alpha-Glutamyl-Tryptophan in the Treatment of Chronic Atrophic Gastritis, Associated with Helicobacter pylori

Abstract

To evaluate the effectiveness of alpha-glutamyl-tryptophan as a cytoprotector in comparison with the control group (placebo) as part of the complex therapy of chronic atrophic H. pylori (HP)-associated gastritis. A total of 121 patients with chronic atrophic HP-associated gastritis were observed in 3 research centers. Before and after treatment blood test “Gastropanel”, stomach endoscopy with biopsies of atrophied mucosa for histological examination, rapid urease test for H. pylori detection, and daily pH-metry were performed. After HP eradication, according to randomization, the study drug (n = 61) or placebo (n = 60) was administered twice a day, in the morning 20–30 minutes before meals and in the evening before bedtime for 28 days. Alpha-glutamyl-tryptophan intake is associated with a statistically significant increase in acidity index according to pH-metry (p = 0.001), an increase in the ratio of pepsinogen I/pepsinogen II (p = 0.003), decrease in the level of gastrin-17 (p = 0.005), increase in the number of glands per 1 mm2 of the gastric mucosa (р = 0.028). Alpha-glutamyl-tryptophan in the treatment of chronic atrophic HP-associated gastritis has a superior regenerative effect compared with placebo, and promotes the restoration of acid-forming and pepsin-forming functions of the stomach.